A 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the 12S rRNA gene of mitochondrial DNA. Studied as a regulator of cellular metabolism, glucose homeostasis, fat oxidation, and exercise adaptation via AMPK pathway activation.
A 39-amino-acid synthetic peptide engineered as a triple agonist of GIP, GLP-1, and glucagon receptors. Eli Lilly research code LY3437943.
A synthetic heptapeptide analog of the immunomodulatory peptide Tuftsin, with a Pro-Gly-Pro C-terminal extension. Studied for anxiolytic, neuromodulatory, and cognitive effects via GABAergic and serotonergic systems.
A synthetic heptapeptide derived from the ACTH(4-10) fragment with a Pro-Gly-Pro C-terminal extension. Studied as a nootropic and neuroprotective compound, typically administered intranasally.
A synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH 1-44), modified with a stabilizing trans-3-hexenoyl group on the N-terminal tyrosine. Marketed clinically as Egrifta; research code TH9507.
A synthetic 39-amino-acid peptide engineered as a dual agonist of the GIP and GLP-1 receptors. Originally developed by Eli Lilly under research code LY3298176.
A research blend pairing BPC-157 (pentadecapeptide) with TB-500 (Thymosin Beta-4 fragment) for tissue repair, angiogenesis, and recovery research.
